Market Research Logo

Global Pharmacovigilance (PV) Market - Segmented by Clinical Trial Phase, Service Provider, Type, End-User and Geography - Growth, Trends and Forecasts (2018 - 2023)

Global Pharmacovigilance (PV) Market - Segmented by Clinical Trial Phase, Service Provider, Type, End-User and Geography - Growth, Trends and Forecasts (2018 - 2023)

According to WHO, Pharmacovigilance is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The focus of pharmacovigilance is on ADR (adverse drug reactions) and drug toxicity. Increasing number of adverse drug reactions (ADRs) imposes a significant burden on the healthcare system by extending patient morbidity under chronic condition. The global pharmacovigilance market is expected to register a CAGR of 12.8% during the forecast period, 2018 to 2023.

Growing Incidence Rates of ADR and Drug Toxicity

The ADR or adverse drug reaction is defined as an injury caused by taking a medication. Adverse drug reactions (ADR) are far more common than one would think. It is estimated that ADR is one of the leading causes of deaths, right after heart disease, cancer, and stroke, globally. Further, it is estimated that ADRs are the sixth leading cause of death worldwide. With the increase in number of adverse drug reactions (ADRs), there has been a significant burden on the healthcare system. The need to reduce the burden of ADRs has led to an increase in the demand for pharmacovigilance services, thus expanding the global market size.

Other factors driving the market growth are increasing drug consumption and drug development rates and increasing trend of outsourcing pharmacovigilance services.

Lack of Skilled Labor

The process of pharmacovigilance requires the use of skilled professionals to manage adverse events and clinical-trial activities, and contribute to ensure compliance of pharmacovigilance activities. However, the dearth of skilled professionals in the market is restraining its growth,

Additionally, high risk associated with data security is also restraining the market growth.

North America to Dominate the Market

North America dominates the market due to rising mortality rates, adverse drug events, and growing patient concerns for safety and efficacy of drugs.


Key Developments in the Market

  • February 2017: PAREXEL announces definitive agreement to acquire the medical affairs company
  • June 2017: Accenture has been named a leader in IDC MarketScape on Life Science Drug Safety Services.
Reasons to Purchase This Report
  • Market analysis for the Global Pharmacovigilance Drugs Market, with region-specific assessments and competition analysis on a Global and regional scale.
  • Analyzing various perspectives of the industry with the help of Porter’s five forces analysis
  • The treatment type that is expected to dominate the market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, market shares and strategies employed by the major market players.
  • 3 months analyst support along with the Market Estimate sheet (in excel)
Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.

1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (Droc)
6.1 Market Drivers
6.1.1 Increasing Drug Consumption and Drug Development Rates
6.1.2 Growing Incidence Rates of ADR and Drug Toxicity
6.1.3 Increasing Trend of Outsourcing Pharmacovigilance Services
6.2 Market Restraints
6.2.1 High Risk Associated with Data Security
6.2.2 Lack of global regulatory harmonization and lack of data standardization for adverse event collection
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Clinical Trial Phase
7.1.1 Preclinical
7.1.2 Phase I
7.1.3 Phase II
7.1.4 Phase III
7.1.5 Phase IV
7.2 By Service Provider
7.2.1 In-house
7.2.2 Contract Outsourcing
7.3 By Type
7.3.1 Spontaneous Reporting
7.3.2 Intensified ADR Reporting
7.3.3 Targeted Spontaneous Reporting
7.3.4 Cohort Event Monitoring
7.3.5 EHR Mining
7.4 By End-User
7.4.1 Hospitals
7.4.2 Pharmaceutical Companies
7.4.3 Others
7.5 By Geography
7.5.1 North America United States Canada Mexico
7.5.2 Europe France United Kingdom Germany Italy Spain Rest of Europe
7.5.3 Asia-Pacific India China Japan Australia South Korea Rest of APAC
7.5.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
7.5.5 South America Brazil Argentina Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations & Partnerships
8.3 New Products Launches
9. Key Players
9.1 Accenture
9.2 Cognizant
9.3 Laboratory Corporation of America Holdings
9.4 IBM Corporation
9.5 ArisGlobal
9.6 Foresight Group International AG
9.7 ICON Plc
9.8 Capgemini
9.9 United BioSource Corporation
9.10 Wipro Ltd.
9.11 BioClinica
9.12 IT Clinical
10. Future of the Market

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report